ReviewDer Nervenarzt2025
[Digital health applications for the treatment of posttraumatic stress disorder : Current state, opportunities, and challenges].
Review in Der Nervenarzt, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the high prevalence of posttraumatic stress disorder (PTSD), no digital health application (digitale Gesundheitsanwendung, DiGA) prescribable within the German statutory health insurance system is currently available to treat the disorder.
objectiveOverview of digital intervention options for the treatment of PTSD and potential challenges in developing an effective DiGA. MATERIAL AND
methodNarrative review of the current literature.
resultsInternet- and mobile-based interventions for PTSD have the potential to serve as an effective treatment option, as demonstrated by a series of meta-analyses comparing them to waiting list control groups, conditions involving no or minimal usual care, and active control groups (e.g., psychoeducation); however, specific challenges exist within the target population that go beyond commonly known barriers, such as pronounced concerns of developers and medical professionals regarding safety and potentially even lower adherence of patients.
conclusionThe development of DiGAs for the treatment of PTSD might be perspectively promising but the aforementioned challenges must be considered in the design and implementation to ensure an effective application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.